Details
Stereochemistry | ACHIRAL |
Molecular Formula | C59H90O4 |
Molecular Weight | 863.3435 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 9 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O
InChI
InChIKey=ACTIUHUUMQJHFO-UPTCCGCDSA-N
InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
Molecular Formula | C59H90O4 |
Molecular Weight | 863.3435 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 9 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.mbschachter.com/coenzyme_q10.htm
https://en.wikipedia.org/wiki/Coenzyme_Q10
Curator's Comment: description was created based on several sources, including
http://www.mbschachter.com/coenzyme_q10.htm
https://en.wikipedia.org/wiki/Coenzyme_Q10
Coenzyme Q10, also known as ubiquinone, ubidecarenone, coenzyme Q, and abbreviated at times to CoQ10 or Q10 is a coenzyme that is ubiquitous in the bodies of most animals. It is a 1,4-benzoquinone, where Q refers to the quinone chemical group and 10 refers to the number of isoprenyl chemical subunits in its tail. This fat-soluble substance, which resembles a vitamin, is present in most eukaryotic cells, primarily in the mitochondria. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. Ninety-five percent of the human body’s energy is generated this way. Therefore, those organs with the highest energy requirements—such as the heart, liver, and kidney—have the highest CoQ10 concentrations. There are three redox states of CoQ10: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and fully reduced (ubiquinol). The capacity of this molecule to act as a 2 electron carrier (moving between the quinone and quinol form) and 1 electron carrier (moving between the semiquinone and one of these other forms) is central to its role in the electron transport chain, and as radical-scavenging antioxidant. Coenzyme Q10 works foremost in every cell of your body to synthesize energy. In cells' mitochondria, CoQ10 helps generate adenosine triphosphate (ATP), your body's energy currency. It makes sense that organs with the highest energy needs - including the heart, liver, and kidneys - contain large amounts of CoQ10. Among its roles, ubiquinol protects fats, protein, low-density lipoprotein (LDL, a cholesterol transporter), and DNA from oxidative damage. It also regenerates vitamin E, another powerful antioxidant. Even though Coenzyme Q10 is a supplement and occurs naturally in your body, it doesn't mean that it's side effect free. However, most CoQ10 side effects are mild. Some people may experience allergies to increased Coenzyme Q10. There have been some reports of rashes and itching. Other side effects include a lowering of blood sugar within the body. CoQ10 is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of any medical condition. It is sold as a dietary supplement. In the U.S., supplements are not regulated as drugs, but as foods. How CoQ10 is manufactured is not regulated and different batches and brands may vary significantly. As an over-the-counter nutritional supplement, CoQ10 has been used to treat many things, from heart disease, high blood pressure and high cholesterol to diabetes, breast cancer and gum disease. CoQ10 supposedly can help with immune deficiencies, increase fertility, treat Alzheimer's and Parkinson's, reduce ringing in the ears, delay aging and improve skin, and increase athleticism The key benefits of coenzyme Q10 are summarized as below. A 2014 Cochrane Collaboration meta-analysis found "no convincing evidence to support or refute" the use of CoQ10 for the treatment of heart failure. Evidence with respect to preventing heart disease in those who are otherwise healthy is also poor. A 2009 Cochrane review concluded that studies looking at the effects of CoQ10 on blood pressure were unreliable, and therefore no conclusions could be made regarding its effectiveness in lowering blood pressure. Available evidence suggests that "CoQ10 is likely ineffective in moderately improving" the chorea associated with Huntington's disease. No large well-designed clinical trials of CoQ10 in cancer treatment have been done. The National Cancer Institute identified issues with the few, small studies that have been done stating, "the way the studies were done and the amount of information reported made it unclear if benefits were caused by the CoQ10 or by something else". The American Cancer Society has concluded, "CoQ10 may reduce the effectiveness of chemo and radiation therapy, so most oncologists would recommend avoiding it during cancer treatment. Lower levels of CoQ10 have also been observed in people with Parkinson's disease. Preliminary research has found that increasing CoQ10 may increase levels of the neurotransmitter dopamine, which is thought to be lowered in people with Parkinson's disease. It has also been suggested that CoQ10 might protect brain cells from damage by free radicals. A small, randomized controlled trial examined the use of 360 mg CoQ10 or a placebo in 28 treated and stable Parkinson's disease patients. After 4 weeks, CoQ10 provided a mild but significant significant mild improvement in early Parkinson's symptoms and significantly improved performance in visual function. As an antioxidant, Coenzyme Q10 helps protect your body against the harmful effects of toxins and also aids the absorption of beneficial vitamins and minerals. Antioxidants are sometimes credited with boosting weight loss, possibly due to their energising effect on the body helping increase the fat-burning benefits of exercise.
CNS Activity
Curator's Comment: CoQ10 (UBIDECARENONE) has been studied for its effect in support of neurological health. When CoQ10 crosses the blood-brain barrier, mitochondrial concentrations are increased and clinical results indicate that significant neurosupportive effects follow. Clinical studies have examined the role of CoQ10 in the neurological system
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006979 Sources: http://www.mbschachter.com/coenzyme_q10.htm |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Unknown Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. | 1978 Jun |
|
Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. | 1985 Mar |
|
A modified determination of coenzyme Q10 in human blood and CoQ10 blood levels in diverse patients with allergies. | 1988 Dec |
|
Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. | 1989 Apr |
|
Coenzyme Q in serum and muscle of 5 patients with Kearns-Sayre syndrome and 12 patients with ophthalmoplegia plus. | 1989 Feb |
|
Lovastatin, isoprenes, and myopathy. | 1989 Nov 4 |
|
Exogenous coenzyme Q (coq) fails to increase coq in skeletal muscle of two patients with mitochondrial myopathies. | 1990 Mar |
|
Effects of inhibitors of hydroxymethylglutaryl coenzyme A reductase on coenzyme Q and dolichol biosynthesis. | 1993 |
|
Coenzyme Q10 levels in human seminal fluid: diagnostic and clinical implications. | 1994 |
|
Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. | 1994 |
|
Aminooxyacetic acid striatal lesions attenuated by 1,3-butanediol and coenzyme Q10. | 1994 Aug 15 |
|
Coenzyme Q10 concentrations in normal and pathological human seminal fluid. | 1994 Nov-Dec |
|
Biochemical, physiological and medical aspects of ubiquinone function. | 1995 May 24 |
|
Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. | 1999 |
|
Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. | 1999 Apr |
|
Blood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemia. | 1999 Jun |
|
Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. | 1999 Mar |
|
Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. | 2005 Feb |
|
Comparative oral toxicity of coenzyme Q10 and its (2Z)-isomer in rats: single and four-week repeated dose toxicity studies. | 2006 Feb |
|
Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism. | 2008 Dec |
|
Gene expression profiling of aging in multiple mouse strains: identification of aging biomarkers and impact of dietary antioxidants. | 2009 Aug |
|
N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes. | 2009 Sep 14 |
|
Cadmium-induced lipid peroxidation and changes in antioxidant defense system in the rat testes: protective role of coenzyme Q(10) and vitamin E. | 2010 Apr |
|
Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice. | 2010 Jul-Aug |
|
Impaired 3',5'-cyclic adenosine monophosphate-mediated signaling in immediate early responsive gene X-1-deficient vascular smooth muscle cells. | 2010 Oct |
|
The reduced form of coenzyme Q10 decreases the expression of lipopolysaccharide-sensitive genes in human THP-1 cells. | 2011 Apr |
|
Drug-induced leukoencephalopathy presenting as catatonia. | 2011 Jan-Feb |
|
Protection of dichlorvos induced oxidative stress and nigrostriatal neuronal death by chronic coenzyme Q10 pretreatment. | 2011 Oct 1 |
|
Coenzyme Q10 protects against amyloid beta-induced neuronal cell death by inhibiting oxidative stress and activating the P13K pathway. | 2012 Jan |
|
Protective efficacy of coenzyme Q10 against DDVP-induced cognitive impairments and neurodegeneration in rats. | 2012 May |
|
Nucleoside reverse transcriptase inhibitors induce a mitophagy-associated endothelial cytotoxicity that is reversed by coenzyme Q10 cotreatment. | 2013 Aug |
|
Coenzyme Q10 protects Pc12 cells from cisplatin-induced DNA damage and neurotoxicity. | 2013 May |
|
Resveratrol stimulates mitochondrial bioenergetics to protect retinal pigment epithelial cells from oxidative damage. | 2013 Sep 27 |
|
Reduction of coenzyme q10 content: a possible effect of isoproterenol on heart failure and myocardial infarction in rat. | 2014 Apr |
|
High selenium impairs hepatic insulin sensitivity through opposite regulation of ROS. | 2014 Jan 3 |
|
Effect of pre- and post-combined multidoses of epigallocatechin gallate and coenzyme Q10 on cisplatin-induced oxidative stress in rat kidney. | 2015 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/15632821
coenzyme Q(10) (UBIDECARENONE) (300 mg/d) for 2 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25800618
peripheral blood mononuclear cells treated with CoQ10 (UBIDECARENONE) showed significantly decreased percentage of Th1 cells (P < 0.005) in pregnant females with history of RPL than in the untreated ones.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:33:29 GMT 2025
by
admin
on
Mon Mar 31 17:33:29 GMT 2025
|
Record UNII |
EJ27X76M46
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C796
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
LOINC |
75050-5
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
LOINC |
27923-2
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
FDA ORPHAN DRUG |
138700
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
FDA ORPHAN DRUG |
335111
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
FDA ORPHAN DRUG |
125099
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
LIVERTOX |
233
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
NCI_THESAURUS |
C275
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
LOINC |
18209-7
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
WHO-ATC |
C01EB09
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
LOINC |
60219-3
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
FDA ORPHAN DRUG |
610717
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
LOINC |
51987-6
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
FDA ORPHAN DRUG |
174603
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
DSLD |
44 (Number of products:2720)
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
WHO-VATC |
QC01EB09
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
FDA ORPHAN DRUG |
822521
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
LOINC |
81156-2
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
||
|
FDA ORPHAN DRUG |
635318
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
303-98-0
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
140865
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
EJ27X76M46
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
DB09270
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
1705301
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
4607
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
C024989
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
COENZYME Q10
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
C916
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
46245
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
C118621
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
ALTERNATIVE | |||
|
100000090312
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
5281915
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
CHEMBL454801
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
D014451
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
140665
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
EJ27X76M46
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
206-147-9
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
m11295
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID6046054
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
10975
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
ALTERNATIVE | |||
|
21406
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
SUB11373MIG
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
46372
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
Coenzyme Q10
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
3463
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
16389
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY | |||
|
C916
Created by
admin on Mon Mar 31 17:33:29 GMT 2025 , Edited by admin on Mon Mar 31 17:33:29 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |